OncoMatch/Clinical Trials/NCT05181735
Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA
Is NCT05181735 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including Luspatercept and Eprex for mds.
Treatment: Luspatercept · Eprex — Study of the combination of luspatercept in low-risk myelodysplastic syndrom (LR-MDS) without ring sideroblasts (RS) having failed or being ineligible to ESA
Check if I qualifyExtracted eligibility criteria
Cancer type
Myelodysplastic Syndrome
Disease stage
Required: Stage LOW, INT-1 (IPSS)
Patients with lower risk MDS according to IPSS classification (LOW, INT-1)
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: erythropoiesis-stimulating agent (EPO-a) — failed to achieve response or relapsed after ESA (at least 60000 U EPO-a over at least 12 weeks or equivalent), or ineligible to ESA defined by EPO > 500 UI/l
who failed to achieved a response or who subsequently relapse after ESA (at least 60000 U EPO-a over at least 12weeks or equivalent), without disease progression (or ineligible to ESA defined by EPO > 500 UI/l)
Cannot have received: investigational agent
Exception: hydroxyurea
Use of investigational agents within 30 days or any anticancer therapy (including IMiD) within 2 weeks before the study entry with the exception of hydroxyurea
Cannot have received: erythropoiesis-stimulating agent (EPO)
Use of EPO within 4 weeks before the study entry
Lab requirements
Kidney function
creatinine less than 1.5 times the upper limit of normal, creatinine clearance ≥ 40 ml/min (mdrd formula)
Liver function
total bilirubin and transaminases less than 1.5 times the upper limit of normal
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify